{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.41","upperLimit":"99.37","value":"75.0"},{"groupId":"OG001","lowerLimit":"6.76","upperLimit":"93.24","value":"50.0"},{"groupId":"OG002","lowerLimit":"9.43","upperLimit":"99.16","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who achieved a stable disease (SD) or better during the study based on the investigator's disease assessment as defined by IMWG uniform response criteria. SD was defined as no known evidence of progressive disease or new bone lesions. Percentages were rounded off to the nearest single decimal place.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 2 mg pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg"},{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 4 mg pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG001","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg"},{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 20/70 milligrams per meter square (mg/m\\^2) carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG002","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2"}],"paramType":"NUMBER","populationDescription":"The Response-Evaluable Analysis Set was a subset of SAS including participants with measurable disease at baseline and at least 1 post-baseline efficacy evaluation. Due to early termination of the study no participants were enrolled in Group 2 Arm 4: modakafusp alfa + bortezomib and Group 3 arms, thus they are not presented here. Also, no participants in Group 1 fulfilled the criteria for the Response-Evaluable Analysis Set and hence are not presented here.","reportingStatus":"POSTED","timeFrame":"Up to 16.7 months","title":"Groups 2 and 3: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}